SUTRO BIOPHARMA, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.465 USD | -6.85% |
|
-8.55% | -19.00% |
Financials (USD)
| Sales 2024 * | 71.73M | Sales 2025 * | 60.34M | Capitalization | 286M |
|---|---|---|---|---|---|
| Net income 2024 * | -217M | Net income 2025 * | -260M | EV / Sales 2024 * | 1.7 x |
| Net cash position 2024 * | 164M | Net cash position 2025 * | 368M | EV / Sales 2025 * | -1.36 x |
| P/E ratio 2024 * |
-1.13
x | P/E ratio 2025 * |
-1.14
x | Employees | 302 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.03% |
More Fundamentals
* Assessed data
More news
Latest transcript on Sutro Biopharma, Inc.
More recommendations
More press releases
More news
| 1 day | -1.33% | ||
| 1 week | -5.58% | ||
| Current month | -34.16% | ||
| 1 month | +8.77% | ||
| 3 months | -22.66% | ||
| 6 months | +26.10% | ||
| Current year | -13.29% |
1 week
3.55
3.94
1 month
3.216.13
Current year
3.206.13
1 year
2.016.13
3 years
2.0123.70
5 years
2.0128.30
10 years
2.0128.30
| Managers | Title | Age | Since |
|---|---|---|---|
William Newell
CEO | Chief Executive Officer | 66 | 09-01-13 |
Jane Chung
PSD | President | 53 | 21-08-08 |
Edward Albini
DFI | Director of Finance/CFO | 66 | 13-01-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Connie Matsui
CHM | Chairman | 70 | 19-06-23 |
James Panek
BRD | Director/Board Member | 71 | 20-01-06 |
Daniel Petree
BRD | Director/Board Member | 68 | - |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.04% | 0 M€ | 0.00% | - | |
| 0.02% | 0 M€ | 0.00% | - | |
| 0.01% | 9 M€ | +5.94% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 3.478 | -6.51% | 333 764 |
| 24-04-23 | 3.72 | -1.33% | 722,440 |
| 24-04-22 | 3.77 | +3.86% | 515,209 |
| 24-04-19 | 3.63 | -3.71% | 515,911 |
| 24-04-18 | 3.77 | -0.79% | 770,412 |
Delayed Quote Nasdaq, April 23, 2024 at 04:00 pm EDT
More quotes
Sutro Biopharma, Inc. is a clinical-stage oncology company. The Company is engaged in developing site-specific and novel-format antibody drug conjugates (ADCs) enabled by its integrated cell-free protein synthesis platform, XpressCF, and its site-specific conjugation platform, XpressCF+. The Companyâs advanced product candidate is STRO-002 (luveltamab tazevibulin, or luvelta), an ADC directed against folate receptor-alpha (FolRa), for patients with FolRa-expressing cancers, including ovarian cancer. In addition, it uses luvelta to treat pediatric patients with relapsed/refractory CBFA2T3-GLIS2 and acute myeloid leukemia. It also has two preclinical product candidates, STRO-003 and STRO-004. These product candidates are single homogeneous ADCs directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1), and tissue factor (TF), each of which is being developed for the treatment of solid tumors.
Calendar
2024-05-13
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
3.72
USD
Average target price
12.89
USD
Spread / Average Target
+246.48%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -13.29% | 286M | |
| -0.49% | 105B | |
| +3.31% | 97.5B | |
| +1.66% | 22.19B | |
| -16.16% | 21.33B | |
| -6.82% | 18.68B | |
| -41.41% | 16.6B | |
| -22.87% | 14.52B | |
| +6.32% | 14.09B | |
| +21.46% | 10.99B |
- Stock Market
- Equities
- STRO Stock
